TEXARKANA, Texas, Jul 25, 2008 (BUSINESS WIRE) -- LecTec Corporation (OTCBB: LECT) announced today that it has filed
a Complaint for patent infringement against Chattem, Inc., Endo
Pharmaceuticals, Inc., Johnson & Johnson Consumer Company, Inc., The
Mentholatum Company, Inc. and Prince of Peace Enterprises, Inc. in the
U.S. District Court for the Eastern District of Texas. The Complaint
alleges, among other things, that the defendants have infringed two of
LecTec's patents relating to its medicated patch technology. LecTec is
seeking to enjoin the defendants from infringing the two patents and
to recover monetary damages relating to such infringement, as well as
interest and litigation costs.

About LecTec Corporation

LecTec Corporation is an intellectual property licensing and
holding company. The Company's primary focus is to derive royalty and
other income from patents that the Company owns based on its advanced
skin interface technologies. The Company was an innovator in
hydrogel-based topical delivery of therapeutic over-the-counter
medications, which provide alternatives to topical creams and
ointments. A hydrogel is a gel-like material having an affinity for
water and similar compounds. These gels are ideal for delivering
medication onto the skin. The Company holds multiple domestic and
international patents on its hydrogel technology.

Cautionary Statements

This press release contains forward-looking statements concerning
possible or anticipated future results of operations or business
developments which are typically preceded by the words "believes,"
"wants," "expects," "anticipates," "intends," "will," "may," "should,"
or similar expressions. Such forward-looking statements are subject to
risks and uncertainties, which could cause results or developments to
differ materially from those, indicated in the forward-looking
statements. Such risks and uncertainties include, but are not limited
to, the Company's dependence on royalty payments from Novartis
Consumer Health, Inc. ("Novartis"), which sells an adult vapor patch
under a license from the Company, the Company's dependence on key
personnel and Board of Director members, the success or failure of any
attempt by the Company to protect or enforce its patents and
territories of coverage, the issuance of new accounting
pronouncements, the availability of opportunities for licensing
agreements related to patents that the Company holds, limitations on
market expansion opportunities, and other risks and uncertainties
detailed from time to time in the Company's filings with the
Securities and Exchange Commission, and particularly as described in
the "Cautionary Statements" filed as Exhibit 99.01 to our Form 10-KSB
for the year ended December 31, 2007.

SOURCE: LecTec Corporation

LecTec Corporation
Bill Johnson, Controller, 903-832-0993

Copyright Business Wire 2008